Nouscom
Basel, Basel-City, Switzerland · Biotechnology, Health Care, Therapeutics
Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high immunogenicity in patients.
Key facts
- Headquarters
- Basel, Basel-City, Switzerland
- Employees
- 11
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- nouscom.com
- Company page
Recent activity at Nouscom
- : Clinical-stage cancer biotech Nouscom raises $135M in Series D funding to advance its lead cancer vaccine through Phase 2 trials.
- : Nouscom Appoints Eckhard Niemeier as Chief Business Officer
- : Nouscom promotes Tiffany Muller to Chief Financial Officer (CFO) and Loredana Siani, Ph.D., to Senior Vice President (SVP), Technical and CMC Development
- : Angelini Ventures invests into extended €75.8 million Series C financing round for Nouscom to advance neoantigen cancer vaccines
- : Nouscom Raises €67.5 Million ($72 Million) In Oversubscribed Series C Financing Round
Nouscom funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Series D | $135.0M |
| Mar 2024 | Series C | $75.8M |
| Nov 2023 | Series C | $67.5M |
Leadership
- Eckhard Niemeier, Chief Business Officer
- Loredana Siani, Vice President
- Tiffany Muller, Chief Financial Officer
- Sven Gogov, Chief Medical Officer
- Richard Davis, Chief Operating Officer
Verified email and direct lines for Nouscom’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Nouscom in the news
- Nouscom raises $135M for pivotal trial of cancer-preventing vaccine candidate - Fierce Biotech (Oct 19, 2026)
- Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO - Yahoo Finance UK (Oct 19, 2026)
- Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial - Nature (Jan 16, 2026)
- Italy’s angels & incubators and venture capital weekly roundup. News from Nouscom, Even Healthcare, Active Label, M Ventures, Revelation Partners, Neva, Angelini Investments, Aurea, European Investment Bank, Angelini Ventures, and more – BeBeez Inter - BeBeez International (Oct 20, 2026)
- Nouscom Selected for Oral Presentation on NOUS-209 Re-treatment and Long-Term Follow-Up in Lynch Syndrome Carriers at ESMO Congress 2026 - Yahoo Finance UK (Jul 20, 2026)
- Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers - Yahoo Finance (Jun 01, 2026)
- The Philosophy Guild (guest post) - Daily Nous (Aug 16, 2022)
Companies similar to Nouscom
- Aqua Medical · Biotechnology, Health Care, Therapeutics
- Atrium Therapeutics · Biotechnology, Health Care, Therapeutics
- Ensho Therapeutics · Biotechnology, Health Care, Therapeutics
- Estuary Biotherapeutics · Biotechnology, Health Care, Therapeutics
- AL-S Pharma AG · Biotechnology, Health Care, Therapeutics
About Nouscom: questions and answers
What does Nouscom do?
Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high immunogenicity in patients.
Where is Nouscom headquartered?
Nouscom is headquartered in Basel, Basel-City, Switzerland.
How many employees does Nouscom have?
Nouscom has about 11 employees.
Has Nouscom raised funding?
Yes. Fundz has recorded 3 funding events for Nouscom. The most recent, Series D of $135.0M, was in Oct 2026.
Who leads Nouscom?
Loredana Siani is a Vice President at Nouscom.
What is the latest news on Nouscom?
On Oct 19, 2026, Clinical-stage cancer biotech Nouscom raises $135M in Series D funding to advance its lead cancer vaccine through Phase 2 trials.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy